Published in Cancer Res on March 10, 2009
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
BAYESIAN MODEL SEARCH AND MULTILEVEL INFERENCE FOR SNP ASSOCIATION STUDIES. Ann Appl Stat (2010) 1.66
The inherited genetics of ovarian and endometrial cancer. Curr Opin Genet Dev (2010) 1.32
Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer. PLoS One (2010) 1.28
Global ovarian cancer health disparities. Gynecol Oncol (2012) 1.24
A multi-center population-based case-control study of ovarian cancer in African-American women: the African American Cancer Epidemiology Study (AACES). BMC Cancer (2014) 1.08
Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.02
WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis (2011) 1.00
The scaffold protein WRAP53β orchestrates the ubiquitin response critical for DNA double-strand break repair. Genes Dev (2014) 0.99
WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients. BMC Cancer (2012) 0.91
Genomics of the NF-κB signaling pathway: hypothesized role in ovarian cancer. Cancer Causes Control (2011) 0.91
Association of common WRAP 53 variant with ovarian cancer risk in the Polish population. Mol Biol Rep (2012) 0.90
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst (2015) 0.90
Risk of ovarian cancer and inherited variants in relapse-associated genes. PLoS One (2010) 0.90
Overexpression of WRAP53 is associated with development and progression of esophageal squamous cell carcinoma. PLoS One (2014) 0.88
Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer. Twin Res Hum Genet (2010) 0.87
Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk. Mol Carcinog (2010) 0.86
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Hum Mol Genet (2011) 0.85
Polymorphism in the GALNT1 gene and epithelial ovarian cancer in non-Hispanic white women: the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev (2010) 0.84
Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacol Toxicol (2015) 0.83
On the road with WRAP53β: guardian of Cajal bodies and genome integrity. Front Genet (2015) 0.83
TP53 genetic polymorphisms, interactions with lifestyle factors and lung cancer risk: a case control study in a Chinese population. BMC Cancer (2013) 0.82
The proximity ligation assay reveals that at DNA double-strand breaks WRAP53β associates with γH2AX and controls interactions between RNF8 and MDC1. Nucleus (2015) 0.81
Downregulation of the cancer susceptibility protein WRAP53β in epithelial ovarian cancer leads to defective DNA repair and poor clinical outcome. Cell Death Dis (2015) 0.81
The Sub-Cellular Localization of WRAP53 Has Prognostic Impact in Breast Cancer. PLoS One (2015) 0.78
Polymorphisms in TP53 are associated with risk and survival of osteosarcoma in a Chinese population. Int J Clin Exp Pathol (2015) 0.78
Overexpression of WDR79 in non-small cell lung cancer is linked to tumour progression. J Cell Mol Med (2016) 0.78
Overexpression of the scaffold WD40 protein WRAP53β enhances the repair of and cell survival from DNA double-strand breaks. Cell Death Dis (2016) 0.78
Telomerase Cajal body protein 1 depletion inhibits telomerase trafficking to telomeres and induces G1 cell cycle arrest in A549 cells. Oncol Lett (2014) 0.76
Genetics and women's health issues--the commitment of EMS to women scientists and gender-associated disease topics. Environ Mol Mutagen (2010) 0.75
Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genet Epidemiol (2015) 0.75
Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype. Oncotarget (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
The International HapMap Project. Nature (2003) 73.65
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet (2003) 21.52
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Regulation and function of the p53 tumor suppressor protein. Curr Opin Cell Biol (2001) 3.46
Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35
Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol (1987) 3.22
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A (1996) 2.30
Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer (2008) 2.14
Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer (2008) 1.82
Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil Steril (2004) 1.81
A prospective study of dietary flavonoid intake and incidence of epithelial ovarian cancer. Int J Cancer (2007) 1.76
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev (2008) 1.73
Germline polymorphism of p53 codon 72 in gynecological cancer. Gynecol Oncol (2005) 1.49
Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2003) 1.49
Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res (2005) 1.45
Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev (2000) 1.44
Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev (2007) 1.39
Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis (2006) 1.35
Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol (2004) 1.31
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.26
A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer (2003) 1.15
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br J Cancer (1999) 1.03
p53 polymorphism in ovarian and bladder cancer. Lancet (1995) 1.00
Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol (2004) 0.98
p53 polymorphism in ovarian and breast cancer. Lancet (1996) 0.95
Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol (1994) 0.92
The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis. Cancer Gene Ther (1997) 0.90
P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur J Cancer Prev (2004) 0.89
An intron binding protein is required for transformation ability of p53. Nucleic Acids Res (1991) 0.88
Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study. Anticancer Res (2003) 0.87
TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer (1998) 0.85
Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients. Anticancer Res (2002) 0.85
P53 codon 72 polymorphism and BRCA 1 and 2 mutations in ovarian epithelial malignancies in black South Africans. Int J Gynecol Cancer (2003) 0.84
Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma. Oncol Rep (1999) 0.80
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA (2006) 24.01
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
International network of cancer genome projects. Nature (2010) 20.35
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst (2004) 19.00
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature (2008) 16.10
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA (2002) 15.59
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31
Body-mass index and mortality among 1.46 million white adults. N Engl J Med (2010) 13.34
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A (2006) 10.32
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet (2011) 8.57
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature (2004) 8.35
A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet (2009) 8.30
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature (2009) 8.12
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
A common genetic risk factor for colorectal and prostate cancer. Nat Genet (2007) 7.11
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99
Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet (2008) 6.97
A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res (2006) 6.91
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet (2005) 6.70
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst (2006) 6.41